Javier Martinez-Picado

发表

Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus

Christos J. Petropoulos, Terri Wrin, Lidia Ruiz, 2006, The Journal of experimental medicine.

Drug uptake transporters in antiretroviral therapy.

Bonaventura Clotet, B. Clotet, J. Martinez-Picado, 2011, Pharmacology & therapeutics.

Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1

J. Martinez-Picado, R. D’Aquila, L. Sutton, 1999, Journal of Virology.

HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics

Michael J. Piovoso, Ryan Zurakowski, Rutao Luo, 2012, PloS one.

Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts

Lidia Ruiz, Bonaventura Clotet, Eugènia Negredo, 2002, HIV clinical trials.

Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein

Philip J. R. Goulder, I. Brierley, J. Martinez-Picado, 2008, Journal of Virology.

Detailed Characterization of Early HIV-1 Replication Dynamics in Primary Human Macrophages

Barbara Müller, Hans-Georg Kräusslich, J. Martinez-Picado, 2018, Viruses.

Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls

Paul J. McLaren, Jacques Fellay, David B. Goldstein, 2013, PLoS pathogens.

Common Genetic Variation and the Control of HIV-1 in Humans

Elizabeth T. Cirulli, Huldrych F. Günthard, Jacques Fellay, 2009, PLoS genetics.

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

Jordi Villà-Freixa, Jorge Carrillo, Cristina Vilaplana, 2017, Scientific Reports.

Alternation of Antiretroviral Drug Regimens for HIV Infection

Lidia Ruiz, Kurt Hertogs, Ayumi Shintani, 2003, Annals of Internal Medicine.

Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1

Christos J. Petropoulos, Terri Wrin, Simon D. W. Frost, 2005, Journal of Virology.

Modelling HIV-1 2-LTR dynamics following raltegravir intensification

Michael J. Piovoso, Hulin Wu, Ryan Zurakowski, 2013, Journal of The Royal Society Interface.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Steven M. Holland, Amelia Licari, Gian Luigi Marseglia, 2020, Science.

A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

Jacques Fellay, David B. Goldstein, Stylianos E. Antonarakis, 2007, Science.

Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence

Ryan Zurakowski, Mario Stevenson, R. Zurakowski, 2018, Retrovirology.

Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy

Michael J. Piovoso, Ryan Zurakowski, Rutao Luo, 2011, PloS one.

Persistent HIV-1 replication during antiretroviral therapy

Steven G. Deeks, J. Martinez-Picado, S. Deeks, 2016, Current opinion in HIV and AIDS.

A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control

David Heckerman, Jacques Fellay, Christoph Lippert, 2013, eLife.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Sarah Palmer, Roger Paredes, Viktor Dahl, 2010, Nature Medicine.